DDInter287 DDInter1376
Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways such as STAT3, PI3K/ATK, and RAS/MAPK. Mutations in _MET_ have been detected in non-small cell lung cancer (NSCLC), and the prevalence of _MET_ amplification in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-naive patients with NSCLC has been reported to be 1.4% - 21%. This co-occurrence has made c-Met a desirable target in the treatment of NSCLC
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Capmatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pantoprazole
Capmatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troglitazone
Capmatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elagolix
Capmatinib {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Capmatinib {u} may lead to a major life threatening interaction when taken with {v} Lumacaftor
Capmatinib may cause a minor interaction that can limit clinical effects when taken with Pantoprazole
Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone
Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Capmatinib may lead to a major life threatening interaction when taken with Lorlatinib
Capmatinib may lead to a major life threatening interaction when taken with Lumacaftor